Bispecific antibodies (bsAbs) enable enhanced therapeutic efficacy through dual-targeting, but their complex structure poses significant manufacturing and purification challenges that require innovative solutions to ensure product purity and clinical viability.
A structured approach that integrates deep technical expertise, advanced process solutions, and scalable, flexible infrastructure is essential to effectively address the complex and evolving challenges of multispecific antibody development, manufacturing, and commercialization.
This presentation addresses the critical need for high-throughput, reliable analytical development strategies that support the rapid progression of multispecific antibody candidates toward expedited Investigational New Drug (IND) applications and early clinical success.
Samsung Biologics is a fully integrated, end-to-end CDMO service provider offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish for biologics. With commercialization in mind, we expand our development portfolio and continue to offer better service to fit clients' needs. Our facilities are cGMP compliant with bioreactor sizes ranging from small to large scale, enabling us to better serve the various needs of our clients and to meet growing biomanufacturing demands.
